* Anavex presents 31-week efficacy data from phase 2a study of ANAVEX 2-73 in alzheimer's patients at AAIC 2016
LONDON, July 27 Scientists in Germany have discovered a bacteria hiding out in peoples' noses that produces an antibiotic compound that can kill several dangerous pathogens, including the superbug MRSA.
* As of June 30, 2016, cash and cash equivalents amounted to 3.2 million euros ($3.52 million) Source text for Eikon: Further company coverage: ($1 = 0.9101 euros) (Gdynia Newsroom)
* H1 revenue 783,000 euros ($860,360.40) versus 731,000 euros year ago Source text: http://bit.ly/2avQ4wZ Further company coverage: ($1 = 0.9101 euros) (Gdynia Newsroom:)
* Vectura initiates legal proceedings against GlaxoSmithKline Plc (GSK)
No related earnings announcements are currently scheduled within the next 7 days.